To switch (statins) or not to switch? That is the question

Bibliography

• Willey VJ, Reinhold JA, Willey KH, Clinical and economic outcomes in patients switched to simvastatin in a community-based family medicine practice. Int J Clin Pract 2010;64:1235-8
   PubMed Web of Science ®Google Scholar
• Hess G, Sanders KN, Hill J, Liu LZ. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. Am J Manag Care 2007;13(Suppl 3):S80-5
   PubMed Web of Science ®Google Scholar
• Corp EV, Antoniou S, Wright PG, Use and cost of branded and generic drugs in patients with coronary heart disease–results from a prospective survey of 1008 patients in two London hospitals. QJM 2009;102:843-9
   PubMed Web of Science ®Google Scholar
• Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008;62:480-4
   PubMed Web of Science ®Google Scholar
• Miller AE, Hansen LB, Saseen JJ. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy 2008;28:553-61
   PubMed Web of Science ®Google Scholar
• Soini EJ, Davies G, Martikainen JA, Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin 2010;26:25-36
   PubMed Web of Science ®Google Scholar
• Fox KM, Gandhi SK, Ohsfeldt RL, Davidson MH. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care 2007;13(Suppl 10):S270-5
   Web of Science ®Google Scholar
• Guthrie RM. Rising to the challenge of treating high-risk patients. Am J Manag Care 2006;12(11 Suppl):S318-24
   Google Scholar
• Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010;105:69-76
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 2008;7:717-25
   PubMed Web of Science ®Google Scholar
• Thiebaud P, Patel BV, Nichol MB, Berenbeim DM. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005;11:670-4
   PubMed Web of Science ®Google Scholar
• Colivicchi F, Tubaro M, Santini M. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes. Int J Cardiol 2010. [Epub ahead of print]
   Google Scholar
• Phillips B, Roberts C, Rudolph AE, Switching statins: the impact on patient outcomes. Br J Cardiol 2007;14:280-5
   Google Scholar
• Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 2007;93:914-21
   PubMed Web of Science ®Google Scholar
• Cannon CP, Steinberg BA, Murphy SA, Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Atorvastatin: safety and tolerability. Expert Opin Drug Saf 2010;9:667-74
   PubMed Web of Science ®Google Scholar
• Atar D, Carmena R, Clemmensen P, Clinical review: impact of statin substitution policies on patient outcomes. Ann Med 2009;41:242-56
   PubMed Web of Science ®Google Scholar
• Hoshiga M, Arishiro K, Nakakoji T, Switching to aggressive statin improves vascular endothelial function in patients with stable coronary artery disease. J Atheroscler Thromb 2010;17:705-11
   PubMed Web of Science ®Google Scholar
• Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 2005;96:61F-68F
   Google Scholar
• Salam AM. Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials. Expert Opin Investig Drugs 2004;13:707-13
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Tziomalos K, Pleiotropic effects of statins–clinical evidence. Curr Pharm Des 2009;15:479-89
   PubMed Web of Science ®Google Scholar
• Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998;352:1830-1
   PubMed Web of Science ®Google Scholar